Low dose rate (LDR) brachytherapy for Prostate Cancer

Phase-Based Progress Estimates
Prostate CancerLow dose rate (LDR) brachytherapy - Radiation
18 - 75
What conditions do you have?

Study Summary

This trial is testing a new, MR-guided 3D ultrasound technique to see if it can more effectively treat prostate cancer while sparing the surrounding nerves and vessels.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Until study completion with 5 years of follow up

1 month after intervention
Rate of patients receiving this experimental brachytherapy technique and achieving acceptable dose distribution at 1-month post-implant.
Month 60
Acute and long-term GU and GI toxicity
Biochemical failure
Number of patient with preserved erectile function Erectile Function (IIEF) >= 18)
Month 60
Post-procedure PSA dynamic
Year 5
Local recurrence

Trial Safety

Trial Design

1 Treatment Group

Prostate Cancer Patients
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Low dose rate (LDR) brachytherapy · No Placebo Group · N/A

Prostate Cancer Patients
Experimental Group · 1 Intervention: Low dose rate (LDR) brachytherapy · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: until study completion with 5 years of follow up

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
613 Previous Clinical Trials
402,111 Total Patients Enrolled
15 Trials studying Prostate Cancer
635 Patients Enrolled for Prostate Cancer
Lucas Mendez, MDPrincipal InvestigatorLondon Health Sciences Centre- London Regional Cancer Program

Eligibility Criteria

Age 18 - 75 · Male Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have low- or favourable intermediate-risk prostate cancer.
You have no contraindications to prostate LDR brachytherapy.
You have no or mild erectile function impairment (score ≥18 in IIEF-5).